Compare · GIA vs TMDX
GIA vs TMDX
Side-by-side comparison of GigCapital 5 Inc. (GIA) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GIA and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.57B, about 8.8x GIA ($292.5M).
- TMDX has hit the wire 6 times in the past 4 weeks while GIA has been quiet.
- TMDX has more recent analyst coverage (19 ratings vs 0 for GIA).
- Company
- GigCapital 5 Inc.
- TransMedics Group Inc.
- Price
- $3.62-13.81%
- $74.39+2.88%
- Market cap
- $292.5M
- $2.57B
- 1M return
- -
- -4.21%
- 1Y return
- -
- -29.31%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 19
GigCapital 5 Inc.
GigCapital5, Inc. is a blank check company. The company was incorporated in 2021 and is based in Palo Alto, California.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest GIA
- Catalyze Partners Appoints Raanan Horowitz to Board of Advisors
- SEC Form 8-K filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- SEC Form SC 13D filed by GigCapital 5 Inc.
- GigCapital 5 Inc. filed SEC Form 8-K: Other Events
- SEC Form 3 filed by new insider Budagov Stas
- SEC Form 3 filed by new insider Weiner Zeev
- SEC Form 3 filed by new insider Dickson Daniel
- SEC Form 3 filed by new insider Taylor Ross
- GigCapital 5 Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Latest TMDX
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)
- President & CEO Hassanein Waleed H was granted 49,669 shares, increasing direct ownership by 41% to 171,093 units (SEC Form 4)
- TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
- Director Gunderson Thomas J. exercised 19,285 shares at a strike of $2.21 and sold $722,377 worth of shares (9,624 units at $75.06), increasing direct ownership by 138% to 16,642 units (SEC Form 4) (for withholding tax)
- SEC Form 144 filed by TransMedics Group Inc.
- SEC Form SD filed by TransMedics Group Inc.
- Director Basile Edward M was granted 2,922 shares, increasing direct ownership by 102% to 5,788 units (SEC Form 4)